Consistent with this explanation, a VICTORIA trial subanalysis found a significant association between baseline NT-proBNP and vericiguat treatment effect, with patients in the lower two quartiles deriving the greatest benefit for the composite outcome of heart failure hospitalization or cardiovascular death [72]. The gene discussed is NPPB; the disease is heart failure.